Research programme: influenza virus nanoparticle therapies - NanoViricides
Alternative Names: FluCide anti-influenza drug candidates - NanoViricides; FluCide™Latest Information Update: 28 Feb 2021
At a glance
- Originator NanoViricides
- Class Antivirals; Polymers
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (IV, Injection)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)